Communication - Press
Elite Member Servier announces FDA approval for VORANIGO®️
The U.S. Food and Drug Administration (FDA) has approved Servier's VORANIGO®, the first and only targeted therapy for Grade 2 IDH-mutant glioma.
This milestone represents the first significant treatment advancement for this type of brain tumor in over 2 decades. Voranigo’s ability to penetrate the blood-brain barrier and reduce tumor progression by 61% offers new hope to patients who previously had limited options.
As the first systemic therapy approved for these IDH-mutant brain cancers, #Voranigo is poised to make a significant impact in the field of neuro-oncology.
